



## SUBSCRIBE

### IPO Report

31<sup>st</sup> Oct '25

#### Snapshot

Company is a direct-to-consumer company that designs and sells a wide range of eyewear products under company's own brands and subbrands. Company design its eyeglasses, both frames and lenses, supported by its 109-member design and merchandising team, as of June 30, 2025. Company offer products across a wide range of price points and age categories, catering to the requirements of an entire household. During the three months ended June 30, 2025 and the Financial Year 2025, company launched 42 and 105 new in-house designed and engineered collections globally, respectively, including in collaboration with popular brands and celebrities

#### VALUATION

Company is bringing the issue at price band of Rs 382-402 per share at ev/ebidta multiple of more than 50x on post issue annualized Q1FY26 basis.

Company has centralized supply chain and automated manufacturing. Also, Company has In-House Frame and Lens engineering and manufacturing capabilities along with Customer-Focused product design capabilities & owned lenskart brand and portfolio of owned sub-brands. Company has technology first approach to customer experience and operational efficiency:

Hence, we recommend "Subscribe" to the issue.

|                                  |                                  |
|----------------------------------|----------------------------------|
| <b>Price Band (Rs./Share)</b>    | <b>382-402</b>                   |
| <b>Opening date of the issue</b> | <b>31<sup>st</sup> Oct '2025</b> |
| <b>Closing Date of the issue</b> | <b>04<sup>th</sup> Nov '2025</b> |
| <b>No of shares pre issue</b>    | 1,68,56,33,793 Eq Shares         |
| <b>Issue Size</b>                | Rs 7023-7278 Cr                  |
| <b>Fresh issue</b>               | Rs 2150 Cr                       |
| <b>Offer For Sale</b>            | 12,75,62,573 Eq Shares           |
| <b>Face Value (Rs/ share)</b>    | Rs 2/share                       |
| <b>Bid Lot</b>                   | 37                               |
| <b>Employee Discount</b>         | Rs 19/share                      |

#### BIDDING DETAILS

|                                |                                                                                                                   |
|--------------------------------|-------------------------------------------------------------------------------------------------------------------|
| <b>QIBs (Including Anchor)</b> | 75% of the offer (Approx 13,55,04,020 Eq Shares)                                                                  |
| <b>Non-Institutional</b>       | 15% of the offer (Approx 2,71,00,803 Eq Shares)                                                                   |
| <b>Retail</b>                  | 10% of the offer (Approx 1,80,67,202 Eq Shares)                                                                   |
| <b>Employee Reservation</b>    | Upto Rs 15 Cr                                                                                                     |
| <b>Lead managers</b>           | Axis Capital, Kotak Mahindra Financial, Morgan Stanley India, Avendus Capital, Citigroup Global, Intensive Fiscal |
| <b>Registrar to the issue</b>  | MUFG Intime India Pvt Ltd                                                                                         |

### WHAT WE LIKE

#### *Company's Direct-to-consumer model*

Company operate a direct-to-consumer model that eliminates multiple layers of intermediaries in the traditional prescription eyeglasses supply chain, enabling company to deliver products to customers at an affordable cost and with next day delivery. This model also allows company to retain end-to-end control over quality, reduce manufacturing lead times, and, according to the Redseer Report, achieve greater cost efficiency compared to conventional eyewear retailers. According to the Redseer Report, company manufactured the third largest number of prescription eyeglasses globally among leading large organized retailers of prescription eyeglasses in Financial Year 2025.

#### *Company's Lenskart Brand and Portfolio of Owned Sub-brands*

Company's Lenskart brand represents its aspiration of allowing people to "Do More" and "Be More". Through its eyewear products, company aim to offer customers a wide and evolving range of choices across occasions, styles, and needs, empowering them to see better every day. In the Financial Year 2025, Lenskart was awarded "India's Most Trusted Eyewear Brand of 2025" by TRA Research.

#### *Company's Omnichannel Retail Network*

Company operate an omnichannel retail network comprising company's mobile applications, websites, and physical stores in India and internationally, aligned with its aspiration to provide Eyewear for All. This enables company to cater to customers who only browse online but prefer to transact at its physical stores. Customers can access company's products and services across channels with consistent pricing (excluding a nominal home-delivery charge) and the ability to purchase, return, and exchange products conveniently through any channel.



## COMPANY BACKGROUND

Company a technology-driven eyewear company with integrated operations spanning designing, manufacturing, branding and retailing of eyewear products. Company primarily sell prescription eyeglasses, sunglasses, and other products such as contact lenses and eyewear accessories. India is its largest market, and according to the Redseer Report, company is the largest seller of prescription eyeglasses in terms of volumes sold in India in Financial Year 2025, among organized retailers. Leveraging company's experience and capabilities in India, company have expanded into select international markets including Japan, Southeast Asia and the Middle East. Company is India's largest, and in Asia, are amongst the two largest, organized retailers of prescription eyeglasses in terms of B2C eyeglasses sales volumes during the Financial Year 2025, according to the Redseer Report.

Company commenced its operations in India as an online business in 2010 and opened company's first retail store in New Delhi in 2013. Since then, company have scaled through both the online and offline channels and have established a presence through its retail stores, websites, mobile applications, and other channels. During the three months ended June 30, 2025 and the Financial Year 2025, in India, 3.73 million and 9.94 million customer accounts, respectively, transacted with company, and company sold 6.72 million and 22.91 million units of eyewear, respectively. As of June 30, 2025, company have 2,137 stores in India, of which, 1,831 were owned by company and 306 were franchisee-owned. During the three months ended June 30, 2025 and the Financial Year 2025, company's India segment total revenue as per Ind AS 108 amounted to ₹11,691.84 million and ₹40,604.66 million, respectively, and its India segment results pre-depreciation and amortisation amounted to ₹2,280.77 million and ₹4,894.76 million, respectively, reflecting an India segment total revenue as per Ind AS 108 CAGR of 30.29% and an India segment results pre-depreciation and amortisation CAGR of 111.67% between Financial Years 2023 and 2025. Company is India's largest and fastest-growing eyewear company in terms of revenue from operations for the Financial Years 2025, 2024 and 2023, according to the Redseer Report.

Company's omnichannel model enables it to scale its operations while efficiently investing in its marketing efforts. In India, company's adjusted same-store sales growth ( "SSSG" ) and same-pincode sales growth ( "SPSG" ) was 15.67% and 20.54%, respectively, in the Financial Year 2025.

The strength of company's omnichannel model is reflected in the growth of its customer base. Company's Annual/Quarterly Transacting Customer Account base (which are accounts that have transacted at least once on any of company's online or offline channels in a given Financial Year/Quarter) in India grew at a CAGR of 25.75% between the Financial Years 2023 and 2025, increasing from 6.29 million in the Financial Year 2023, to 8.06 million in the Financial Year 2024 and 9.94 million in the Financial Year 2025, and to 3.73 million during the three months ended June 30, 2025. Company have scaled its business due to the effectiveness of company's end-to-end operating model, which comprises company's in-house design capabilities, centralised supply chain, and manufacturing that allows company to cater to a growing customer base. Similarly, its Annual/Quarterly Transacting Customer Account base in its International markets grew at 15.73% CAGR year-on-year between the Financial Years 2024 and 2025, increasing from 2.14 million in the Financial Year 2024 and 2.47 million in the Financial Year 2025, standing at 0.70 million in the three months ended June 30, 2025.

## OBJECTS OF OFFER

The Offer comprises of a Fresh Issue and an Offer for Sale of Equity Shares by the Selling Shareholders.

### Objects of the Fresh Issue

Company proposes to utilize the Net Proceeds from the Fresh Issue towards funding the following objects (collectively, referred to herein as the "Objects"):

- Capital expenditure towards set-up of new CoCo stores in India;
- Expenditure for lease/rent/license agreements related payments for company's CoCo stores operated by Company in India;
- Investing in technology and cloud infrastructure;
- Brand marketing and business promotion expenses for enhancing brand awareness; and
- Unidentified inorganic acquisitions and
- general corporate purposes..

## RISKS

Company's cost of raw materials consumed constitutes a significant portion of its expenses (amounting to ₹4,673.39 million, or 25.45% and ₹16,229.74 million, or 24.52%, of its total expenses in the three months ended June 30, 2025 and the Financial Year 2025, respectively) and delays, interruptions or reduction in the supply of raw materials to manufacture its prescription eyeglasses or fluctuations in the prices of company's raw materials could adversely affect company's business, results of operations, financial condition and cash flows.

Source:RHP


**Consolidated Financials**

(Rs in Mn)

| Financials              | FY23      | FY24      | FY25      | Q1FY26    |
|-------------------------|-----------|-----------|-----------|-----------|
| Total Revenue (A)       | 37880.28  | 54277.03  | 66525.17  | 18944.55  |
| Total Expenditure (B)   | 35242.43  | 47542.65  | 56770.19  | 15584.11  |
| EBIDTA                  | 2637.85   | 6734.38   | 9754.98   | 3360.44   |
| EBIDTA Margin           | 6.96      | 12.41     | 14.66     | 17.74     |
| Other Income            | 1399.46   | 1821.69   | 3567.59   | 516.46    |
| Depreciation            | 4175.53   | 6722.40   | 7965.69   | 2371.31   |
| EBIT                    | -138.22   | 1833.67   | 5356.88   | 1505.59   |
| Interest                | 832.78    | 1229.89   | 1458.90   | 410.38    |
| PBT                     | -971.00   | 603.78    | 3897.98   | 1095.21   |
| Share of profit in Asso | -40.76    | -12.47    | -44.42    | 5.84      |
| PBIT                    | -1011.76  | 591.31    | 3853.56   | 1101.05   |
| Exceptional             | 0.00      | 0.00      | 0.00      | 103.86    |
| PBT                     | -1011.76  | 591.31    | 3853.56   | 997.19    |
| Tax                     | -374.19   | 691.85    | 880.16    | 385.46    |
| PAT                     | -637.57   | -100.54   | 2973.40   | 611.73    |
| NPM                     | -1.68     | -0.19     | 4.47      | 3.23      |
| ROE%                    | -1.25     | -0.31     | 4.84      | 0.97      |
| EPS                     | -0.43     | -0.11     | 1.77      | 0.36      |
| Eq Cap                  | 152.86    | 154.18    | 1,543.37  | 1,543.37  |
| Net Worth               | 54,738.07 | 56,492.86 | 60,987.34 | 62,157.86 |

(Source: RHP)



## DISCLAIMER

HEM Securities Limited ("Research Entity or HSL") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services, merchant banking services, Portfolio Management Services and other related activities. Broking services offered by HEM Securities Limited are under SEBI Registration No.: INZ000168034.

This Report has been prepared by HEM Securities Limited in the capacity of a Research Analyst having SEBI Registration No. INH100002250 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. This should not be construed as invitation or solicitation to do business with HSL. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject HSL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. HSL reserves the right to make modifications and alterations to this statement as may be required from time to time. HSL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. HSL is committed to providing independent and transparent recommendation to its clients. Neither HSL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance. The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

HSL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.